Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab versus placebo in active psoriatic arthritis
2011-000276-34Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in psoriatic arthritis (PsA) (3 arms), sponsored by Novartis. Primary endpoint: ACR20 response at Week 24. Started Jun 2011; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2011-000276-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000276-34.